img
img
The relationship between homocysteine and no-reflow phenomenon in patients undergoing primary percutaneous coronary intervention     
Yazarlar (9)
Timor Omar
Kafkas Üniversitesi, Türkiye
Prof. Dr. Yavuz KARABAĞ Prof. Dr. Yavuz KARABAĞ
Kafkas Üniversitesi, Türkiye
Prof. Dr. Metin ÖĞÜN Prof. Dr. Metin ÖĞÜN
Türkiye
Doç. Dr. İnanç ARTAÇ Doç. Dr. İnanç ARTAÇ
Kafkas Üniversitesi, Türkiye
Dr. Öğr. Üyesi Muammer KARAKAYALI Dr. Öğr. Üyesi Muammer KARAKAYALI
Kafkas Üniversitesi, Türkiye
Dr. Öğr. Üyesi Doğan İLİŞ Dr. Öğr. Üyesi Doğan İLİŞ
Kafkas Üniversitesi, Türkiye
Ayça Arslan
Türkiye
Cihan Dündar
Türkiye
Prof. Dr. İbrahim RENCÜZOĞULLARI Prof. Dr. İbrahim RENCÜZOĞULLARI
Kafkas Üniversitesi, Türkiye
Devamını Göster
Özet
Aims The current study aimed to investigate the relationship between homocysteine and no-reflow phenomenon in patients undergoing primary percutaneous coronary intervention (pPCI). Methods Patients with ST-elevation myocardial infarctions (STEMI) who underwent pPCI in our center between May 01, 2022, and 20 August 2023 were included in this cross-sectional observational study. Patients were classified into two groups according to the occurrence of no-reflow during pPCI. Findings were compared between the two groups. Results A total of 332 patients [male, 75 (%82.8)] with STEMI undergoing pPCI, were included. Among them, 35 (10.5%) patients developed no-reflow. Homocysteine level was significantly higher in the no-reflow(+) group than the no-reflow(-) group [median (IQR), 19.02 (16.11-22.23 vs. 12.45 (10.99-14.93), p=0.019]. According to the multivariate analysis, homocysteine level, TIMI risk score, and postdilatation were independent predictors of no-reflow occurrence [Odds Ratio (95% CI), 1.127 (1.042-1.218), p=0.003, 1.385 (1.157-1.659), p<0.001, and 2.396 (1.092-5.257), p=0.029, respectively]. Considering the ROC curve analysis for homocysteine predicting no-reflow, the area under the curve (AUC) was 0.714 with an optimal cut-off value of 14.1 (sensitivity of 71%, specificity 62%). Conclusion Higher admission homocysteine levels were associated with no-reflow development in STEMI patients during pPCI. Higher levels of homocysteine may identify a subset of patients at a higher risk of no-reflow development during pPCI.
Anahtar Kelimeler
Makale Türü Özgün Makale
Makale Alt Türü Ulusal alan endekslerinde (TR Dizin, ULAKBİM) yayınlanan tam makale
Dergi Adı Journal of Health Sciences and Medicine
Dergi ISSN 2636-8579
Dergi Tarandığı Indeksler TR DİZİN
Makale Dili Türkçe
Basım Tarihi 03-2024
Cilt No 7
Sayı 2
Sayfalar 199 / 205
Doi Numarası 10.32322/jhsm.1413552
Makale Linki http://dx.doi.org/10.32322/jhsm.1413552